HFPEF MANAGEMENT AND IMPLICATION OF EMPEROR-PRESERVED IN CLINICAL PRACTICE: INSIGHTS FROM INDIAN CARDIOLOGISTS

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a growing burden to the healthcare system due to the lack of proven therapy to reduce mortality and morbidity. Data from the Trivandrum heart failure registry (THFR) reveals that hospital readmissions significantly associated with mortality in patients with HFpEF having a cumulative one-year mortality rate was 27.3%- and three-years mortality was 40.8%.[1] This survey-based study aimed to evaluate the opinion of cardiology experts on the application of EMPEROR-Preserved trial outcomes in clinical practice. This was a cross-sectional poll-based opinion survey conducted during the 10 expert group meetings which included 95 cardiologists between September 2021 and October 2021. The majority (56.8%) of participants mentioned that 20-40% of their HF patients are HFpEF (Table 1). This is in line with the previously reported heart failure registries which indicate a prevalence of HFpEF ranging from 31.2% to 50.4%.[2] Hypertension was the most prevalent comorbidity in Indian HFpEF (97.4%) patients. A total of 96.7% of participants agreed or strongly agreed that HFpEF is underdiagnosed in India (Figure 1).